Immuneering Reports Third-Quarter 2026 Results, Updates Pipeline
Immuneering said pancreatic cancer follow-up in its Phase 2 atebimetinib combination study was extended, with updated data expected in the first half of 2027. The company also said enrollment in its Phase 3 MAPKeeper 301 trial is ahead of schedule.
Story updates
08:10:49 PM UTC
SquawkNews
Immuneering reported Q3 2026 net loss of $24.2M ($0.37/share) and said cash of $166.1M is expected to fund operations into Q4 2028. Phase 3 enrollment is ahead of schedule and the target is expanding to 570 patients.Material DetailsContext by AI AnalystThis is a late-stage clinical update paired wi…